September 19, 2019

Stakeholder Letter to DEA on Ryan Haight Special Registration

H.R. 6353


ATA, along with a number of healthcare stakeholders, submitted a letter with comments on the Drug Enforcement Administration’s (DEA) implementation of a Special Registration provision for telemedicine under the Ryan Haight Act. This letter strongly urged the DEA to consider how the design of the process and criteria for special registrations for controlled substance prescribing through telemedicine can positively or negatively impact patients living with serious, chronic, disabling, and debilitating conditions – such as obesity, insomnia, substance use disorder, and some psychiatric conditions – in underserved communities.